Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof
Pharmaceutically acceptable liposome-encapsulated busulphan formulations for parenteral administration are provided, as well as such formulations furthermore comprising glutathione and/or at least one glutathione precursor and a process for manufacture of the preparations. The formulations are stable, have improved biodistribution and significantly reduced side effects over those produced by oral administration or parenteral administration of free drug. The formulations are useful as part of stem cell and/or bone marrow transplant conditioning regimens. A method of treatment of a mammal by use of such formulations.
1. A liposome composition for myelosuppressive treatment comprising
busulphan encapsulated in liposomes having a size of from 50 to 300 nm;
said liposome composition having a character that, when administered to a mammalian patient, does not accumulate in the patient's liver;
said liposomes having membranes comprising lipids,
wherein the lipids are L-α-phosphatidylcholine, 1,2-dioleolyl-sn-glycero-3-phosphate and cholesterol,
said lipids being present in a molar ratio of about 9.45:1:9.4.
2. A liposome composition for myelosuppressive treatment comprising
busulphan encapsulated in liposomes having a size of from 50 to 300 nm;
said liposome composition having a character that, when administered to a mammalian patient, does not accumulate in the patient's liver;
said liposomes having membranes comprising lipids,
wherein the lipids are at least one of phosphatidylserine, phosphatidylcholine and cholesterol,
said lipids being present in a molar ratio of about 3:7:10.
3. A liposome composition for myelosuppressive treatment comprising
busulphan encapsulated in liposomes having a size of from 50 to 300 nm;
said liposome composition having a character that, when administered to a mammalian patient, does not accumulate in the patient's liver;
said liposomes having membranes comprising lipids,
wherein the lipids are cardiolipin, phosphatidylcholine and cholesterol,
said lipids being present in a molar ratio of about 1:4:1.5.
4. A liposome composition for myelosuppressive treatment comprising
busulphan encapsulated in liposomes having a size of from 50 to 300 nm;
said liposome composition having a character that, when administered to a mammalian patient, does not accumulate in the patient's liver;
said liposomes having membranes comprising lipids,
wherein the lipids are phosphatidylcholine, cholesterol and stearylamine,
said lipids being present in a molar ratio of about 7:1:1.
5. A pharmaceutical composition comprising a liposome composition according to claim 1 and a pharmaceutically acceptable carrier.
6. A pharmaceutical composition according to claim 5 , further comprising glutathione (GSH) and/or at least one GSH precursor compound that through cellular reactions within the body of a mammal is transformed into GSH, and
wherein the GSH precursor compound is selected from the group consisting of N-acetylcysteine, methionine, cysteine, glutamine, cystine, homocysteine, glycine, cysteinylglycine, glutamyl aminoacid, and glutamyl cysteine.
7. A pharmaceutical composition according to claim 6 , wherein the GSH precursor compound is N-acetylcysteine.
8. A method of treating a mammalian patient in need of myelosuppressive treatment comprising parenterally administering to the patient an effective amount of a pharmaceutical composition according to claim 5 .
9. The method according to claim 8 , further comprising administering to the mammalian patient during a period at least partly overlapping with the period of myelosuppressive treatment, a pharmaceutical composition comprising GSH and/or at least one GSH precursor compound that through intracellular reactions within the body of the mammal is transformed into GSH, in a pharmaceutically acceptable carrier,
wherein the GSH precursor compound is selected from N-acetylcysteine, methionine, cysteine, glutamine, cystine, homocysteine, glycine, cysteinylglycine, glutamyl aminoacid, glutamyl cysteine.
10. The method according to claim 8 , wherein the mammalian patient is undergoing a stem cell or bone marrow transplantation.
11. A method of treating a mammalian patient in need of myelosuppressive treatment comprising parenterally administering to the patient an effective amount of a pharmaceutical composition according to claim 6 .
12. A liposome composition according to claim 1 in a dehydrated state.
13. A liposome composition according to claim 1 in a lyophilized state.
14. The method according to claim 9 , wherein said period of administration of composition comprising GSH and/or at least one GSH precursor compound extends over the entire period of myelosuppressive treatment.
15. A pharmaceutical composition comprising a liposome composition according to claim 2 and a pharmaceutically acceptable carrier.
16. A pharmaceutical composition comprising a liposome composition according to claim 3 and a pharmaceutically acceptable carrier.
17. A pharmaceutical composition comprising a liposome composition according to claim 4 and a pharmaceutically acceptable carrier.
18. A pharmaceutical composition according to claim 15 , further comprising glutathione (GSH) and/or at least one GSH precursor compound that through cellular reactions within the body of a mammal is transformed into GSH, and
wherein the GSH precursor compound is selected from the group consisting of N-acetylcysteine, methionine, cysteine, glutamine, cystine, homocysteine, glycine, cysteinylglycine, glutamyl aminoacid, and glutamyl cysteine.
19. A pharmaceutical composition according to claim 16 , further comprising glutathione (GSH) and/or at least one GSH precursor compound that through cellular reactions within the body of a mammal is transformed into GSH, and
wherein the GSH precursor compound is selected from the group consisting of N-acetylcysteine, methionine, cysteine, glutamine, cystine, homocysteine, glycine, cysteinylglycine, glutamyl aminoacid, and glutamyl cysteine.
20. A pharmaceutical composition according to claim 17 , further comprising glutathione (GSH) and/or at least one GSH precursor compound that through cellular reactions within the body of a mammal is transformed into GSH, and
wherein the GSH precursor compound is selected from the group consisting of N-acetylcysteine, methionine, cysteine, glutamine, cystine, homocysteine, glycine, cysteinylglycine, glutamyl aminoacid, and glutamyl cysteine.